OrbiMed’s Novo Nordisk NVO Stock Holding History

OrbiMed’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-660,000	Closed	-$22.9M	–	156
2020 Q3	$22.9M	Hold	660,000	–	–	0.29%	82
2020 Q2	$21.6M	Hold	660,000	–	–	0.3%	73
2020 Q1	$19.9M	Hold	660,000	–	–	0.33%	66
2019 Q4	$19.1M	Hold	660,000	–	–	0.27%	69
2019 Q3	$17.1M	Hold	660,000	–	–	0.32%	68
2019 Q2	$16.8M	Hold	660,000	–	–	0.26%	77
2019 Q1	$17.3M	Hold	660,000	–	–	0.27%	80
2018 Q4	$15.2M	Hold	660,000	–	–	0.28%	76
2018 Q3	$15.6M	Hold	660,000	–	–	0.19%	98
2018 Q2	$15.2M	Hold	660,000	–	–	0.18%	101
2018 Q1	$16.3M	Hold	660,000	–	–	0.2%	86
2017 Q4	$17.7M	Hold	660,000	–	–	0.22%	83
2017 Q3	$15.9M	Buy	+660,000	New	+$14.9M	0.15%	92

Other funds holding NVO

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

EHC

Everett Harris & Co Los Angeles, California $7.77B AUM 9.43% 1-Year Est. Return

OrbiMed's NVO Position: Q4 2020 in Review

OrbiMed sold out of Novo Nordisk (NVO) in Q4 2020, closing a stake of 660,000 shares — an estimated $22.9M sold.

OrbiMed first reported a position in NVO in Q3 2017 and held it in 13 quarters. The position peaked at $22.9M in Q3 2020. 702 funds tracked by Wall St. Rank hold NVO as of Q4 2020.

OrbiMed reported no remaining Novo Nordisk position as of Q4 2020 after selling out during the quarter.
OrbiMed sold 660,000 Novo Nordisk shares in Q4 2020, an estimated $22.9M.
OrbiMed first reported a position in Novo Nordisk in Q3 2017 and held it in 13 quarters.
OrbiMed's Novo Nordisk position peaked at $22.9M in Q3 2020.
702 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2020.

Based on OrbiMed's 13F filing for Q4 2020, filed 16 Feb 2021.